Treatment with CT7001 induces potent growth inhibition and promotes cell cycle arrest in prostate cancer lines with submicromolar potency, while higher drug concentrations can induce activation of the p53 pathway and promote apoptosis. The gene discussed is TP53; the disease is prostate carcinoma.